Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaigui Longmu Ejiao Paste is an investigational Traditional Chinese Medicine (TCM) formulation developed by Longhua Hospital for the treatment of ischemic heart disease, specifically aimed at reducing the frequency of angina attacks. The preparation is a complex herbal mixture, with Ejiao (donkey-hide gelatin) serving as a primary differentiating ingredient compared to standard Chaigui Longmu formulations. It is typically administered orally as an adjunct to standard Western medical treatments. Currently, it is undergoing Phase 2 clinical evaluation to assess its efficacy and safety in patients with stable or unstable angina associated with coronary artery disease. As a TCM product, its therapeutic effect is likely derived from the synergistic action of multiple phytochemical components, though specific biological targets and a detailed mechanism of action remain largely uncharacterized in public literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaigui Longmu Ejiao Paste.